Europe Pediatric Proton Therapy Market - Most Definitive & Accurate Study Upto 2022

Researchmoz added Most up-to-date research on "Europe Pediatric Proton Therapy Market - Most Definitive & Accurate Study Upto 2022" to its huge collection of research reports.

Europe Pediatric Proton Therapy Market has a market potential close to US$ 150 Million by 2022. The rise of pediatric cancer incidence in Europe region and proton therapy gaining prominence and credibility among radiation oncologist will motivate the investor to invest in it. As of now, the pediatric proton therapy is in growing stage in European region. There are so many robust proton therapy center-building is happening across the Europe. United Kingdom is building six proton therapy alone to cater their pediatric cancer patients.

Germany has the Highest Market Share in Pediatric Proton Therapy Market 

Germany captures highest pediatric proton therapy market share as it has launched good number of advanced proton therapy center constantly in the year 2013, 2014 and 2015. France had maximum market share in 2010 but it lost its position and reached to fourth position in 2016. The report studies pediatric proton therapy market share of these 6 countries: France, Germany, Switzerland, Sweden, Czech Republic, United Kingdom. 

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1273818

Rising Prevalence of Pediatric Cancer Patients and Technological Advancement will drive the Pediatric Proton Therapy Market in Europe 

Rising overall cancer diagnosed pediatric patients in Europe will enforce the several countries in Europe to develop proton therapy center according to demand. Technological up-gradation is playing very important role in driving pediatric proton therapy market in Europe. Advanced technology & multi-room trend will cater more patients than earlier. 

  

Europe Pediatric Proton Therapy Market & Forecast (6 Countries Market Data), Patients Treated, Reimbursement Policies is the 15th report published by Renub Research on Proton Therapy Market. This 108 page report with 71 figures and 4 Tables provides 6 Countries: Pediatric Proton Therapy Market, Proton Therapy Patient Numbers, Technology being used at these Proton Therapy Centers and Reimbursement Policies. The report also studies the Proton Therapy Sales & Forecast of four companies IBA, Varian Medical Systems, Mitsubishi, and Hitachi. 

Browse TOC @ https://www.researchmoz.us/europe-pediatric-proton-therapy-market-forecast-6-countries-market-data-patients-treated-reimbursement-policies-report.html/toc

Key Questions Answered in the Report?   

• What is the Pediatric Proton Therapy Market in Europe and its growth potential in Future?
• How many pediatric patients treated by Proton Beam Therapy in Europe?
• What are the reimbursement policies for Proton Therapy across the Europe?
• What is the Pediatric Proton Therapy Market in Germany and its growth potential in Future? 
• How many Pediatric Proton Therapy Patients treated in Germany and Forecast?
• What is the Pediatric Proton Therapy Market in France and its growth potential in Future? 
• How many Pediatric Proton Therapy Patients treated in France and Forecast?
• What is the Pediatric Proton Therapy Market in Sweden and its growth potential in Future? 
• How many Pediatric Proton Therapy Patients treated in Sweden and Forecast?
• What is the Pediatric Proton Therapy Market in Switzerland and its growth potential in Future? 
• How many Pediatric Proton Therapy Patients treated in Switzerland and Forecast?
• What is the Pediatric Proton Therapy Market in Czech Republic and its growth potential in Future?
• How many Pediatric Proton Therapy Patients treated in Czech Republic and Forecast?
• What is the Pediatric Proton Therapy Market in United Kingdom and its growth potential in Future? 
• How many Pediatric Proton Therapy Patients treated in United Kingdom and Forecast?
• What Type of Technology being used at Proton Therapy Centers?

Key Companies Proton Therapy Sales & Forecast

• IBA – Sales Analysis & Forecast (2010 – 2021) 
• Varian Medical Systems – Sales Analysis & Forecast (2010 – 2021) 
• Mitsubishi - Sales Analysis & Forecast (2010 – 2021) 
• Hitachi - Sales Analysis & Forecast (2010 – 2021) 

Six Countries Covered Under this Report

• France
• Germany
• Switzerland
• Sweden
• Czech Republic
• United Kingdom

USA Pediatric Proton Therapy Market To Reach Close To US$ 350 Million By The End Of Year 2021 – Analysis and Forecast

Researchmoz added Most up-to-date research on "USA Pediatric Proton Therapy Market To Reach Close To US$ 350 Million By The End Of Year 2021 – Analysis and Forecast" to its huge collection of research reports.

USA Pediatric Proton Therapy Market has potential to reach close to US$ 350 Million by the end of year 2021. But its actual market is predicted to be less than even half of this figure. The difference between this actual and potential market is due to its demand and supply gap. In United States, the cancer incidence among pediatric is rising at rapid pace. USA has largest and more efficient proton therapy center in world due to long history of its proton therapy research and huge investment on center development.

Age Group of (1-4) has the Largest Cancer Evidence in USA Pediatric Proton Therapy Market

In this report United States pediatric proton therapy market is divided into five age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year. Out of these age groups (1-4) age group has largest market. 

Ependymoma Cancerous Tumor has the Highest Market among 36 Types of Cancer which has been studied in the report

The largest treated pediatric patient with proton therapy in USA is Ependymoma which has almost 15 percent share in United States pediatric proton therapy market. Moreover the ability of proton therapy to treat numerous types of pediatric cancer in a more efficient way than traditional radiotherapy has made it preferential choice for pediatric cancer patients.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1273822

Increasing Cancer Incidence Among Pediatric and Phenomenal Progress in Technological Development of Proton Therapy Across the Period of Time has made it Key driver for Rapid Growth in United States

Proton Therapy has gained prominence in such a short period due to continuous development of cutting-edge technology like intensity-modulated proton therapy (IMPT) and pencil beam technology. Moreover rising cancer incidence among children in United States reinforced pediatric proton therapy market for faster growth.

USA Pediatric Proton Therapy Market, Patient Numbers, Forecast By Age & Tumors (36 Cancer Types Analyzed) is the 16th report published by Renub Research on Proton Therapy Market. This 195 page report with 182 figures and 3 Tables provides: Pediatric Proton Therapy Market, Proton Therapy Patient Numbers (both by Age Group and Type of Tumors) Technology being used at these Proton Therapy Centers. The report also studies the Proton Therapy Sales & Forecast of four companies IBA, Varian Medical Systems, Mitsubishi and Hitachi. 

Browse TOC @ https://www.researchmoz.us/usa-pediatric-proton-therapy-market-patient-numbers-forecast-by-age-tumors-36-cancer-types-analyzed-report.html/toc

Type of Tumors Market & Patient Numbers Studied in the Report

• Glioma, Low Grade
• Glioma, High Grade
• Medulloblastoma
• Ependymoma
• ATRT
• Germinoma, Pure
• Germ Cell Tumor
• Craniopharyngioma
• PNET
• Pineoblastoma
• Chordoma/Chondrosarcoma
• Meningioma
• AVM
• Adenoma
• Choroid Plexus Carcinoma
• Retinoblastoma
• Osteosarcoma
• Ewing Sarcoma
• Rhabdomyosarcoma
• Other Sarcoma, High Grade
• Other Sarcoma, Low Grade
• Teratoma
• Neuroblastoma
• Ganglioglioma
• Wilm’s Tumor
• Carcinoma (non-CPC)
• Lymphoma, Hodgkin’s
• Lymphoma, Non-hodgkin’s
• Leukemia
• Desmoid
• Melanoma
• Pineal Parenchymal Tumor
• Esthesioneuroblastoma
• Angiofibroma
• Extrarenal Rhabdoid Tumor
• Others

Age Group Studied in Report 

1. Age Group (<1) Year
2. Age Group (1-4) Year    
3. Age Group (5-9) Year    
4. Age Group (10-14) Year
5. Age Group (15-18) Year

Key Companies Proton Therapy Sales & Forecast (2010 – 2021) Covered in this report

1. IBA 
2. Varian Medical Systems
3. Mitsubishi 
4. Hitachi 

Key Questions Answered in the Report

• What is the Pediatric Proton Therapy Market in United States and its growth potential in Future
• How Many Pediatric Patients are treated by Proton Beam Therapy in United States
• What is the Pediatric Proton Therapy Market by Age Group age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year in United States and its Forecast
• How Many Pediatric Proton Therapy Patients treated by Age Group age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year in United States and its Forecast
• What is the Pediatric Proton Therapy Market by Tumors (36 Types) in United States and its Forecast
• How Many Pediatric Proton Therapy Patients treated by different Tumor Type in United States and its Forecast
• What Type of Technology is being used at Proton Therapy Centers

Survey Report: Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

Researchmoz added Most up-to-date research on "Survey Report: Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" to its huge collection of research reports.

Genetic modification therapies are changing the landscape of medicine due to their unprecedented ability to offer a one-time cure for severe, debilitating diseases that were previously untreatable. Genetic modification therapies are advanced therapies that use genetic material (i.e., DNA or RNA) to treat diseases.

The four main genetic modification therapy platform technologies covered in this report include gene therapies, genetically modified cell therapies, RNA therapies and gene editing.

In Dec. 2017, Luxturna became the first gene therapy approved for treating a genetic disorder. Luxturna is indicated for treating a severe inherited retinal disorder caused by a mutation in a single gene. Luxturna meets a clear and pressing medical need of restoring functional vision to a patient.

Besides Luxturna, several genetic modification therapies have been approved, including Kymarih and Yescarta (genetically modified cell therapy), Spinraza (RNA therapy) and others, setting the stage for strong market growth in the next five years.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1895400

Reasons for Doing the Study
Genetic modification therapies, particularly gene therapy and RNA therapy, have existed for many years, with little clinical success. However, recent improvements in these therapies, including better delivery systems, more efficient and durable gene expression constructs, precise DNA editing tools, have brought this industry to the forefront, and it is now poised for explosive growth in the coming years.

Because of the potentially curative nature of these medicines there is enormous potential in many applications, ranging from cancer to neurology to rare diseases. Genetic modification therapies represent the next wave of medicines with enormous potential for treating and curing debilitating and serious diseases. Because of its wide scope, genetic modification therapy will play an important role in the future global medical economy.

Continuing advances in key technologies such as DNA editing, viral design and production, and gene expression, as well as a pressing medical need in many serious and debilitating disorders, are driving the growth of the market for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for genetic modification therapy products.

Browse TOC @ https://www.researchmoz.us/genetic-modification-therapies-clinical-applications-gene-therapies-genetically-modified-cell-therapies-rna-therapies-and-gene-editing-report.html/toc

Based on these market and technology dynamics, it is especially timely to comprehensively examine the current and future markets for genetic modification therapies."

"Report Scope:
The study scope includes clinical therapies using gene editing, gene therapy, genetically modified cell therapy (chimeric antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms. Delivery technologies covered include AAV, adenovirus, lentivirus, retrovirus, other viral and nonviral. Disease areas covered include cardiology, oncology, ophthalmology, hematology, musculoskeletal, neurology, rare diseases and others. Therapies that are already commercialized or are forecast to be commercialized with the next five years are included.

We analyze key genetic modification therapy technologies and products to determine present and future market status and forecasted growth from 2018 through 2023. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.

BCC Research examines the genetic modification therapies industry by market segment, including the following segments: gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production. The geographic market for genetic modification therapy products by platform technology is analyzed. Regions include North America, Europe, Asia-Pacific and the rest of the world.

The role of key strategic alliances and acquisitions from Jan. 2016 through June 2018 is discussed.

The challenges involved with pricing for genetic modification therapies that can offer one-time cures for diseases is discussed. Emerging markets for clinical gene editing are analyzed. More than 145 companies in the genetic modification therapies industry are profiled.

Report Includes:
- 30 data tables and 56 additional tables
- An overview of the global market for genetic modification therapies
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on the genetic variation analysis and genetic modification technologies
- Evaluation of key growth driving forces, acquisitions and strategic alliances related to the market
- Detailed description of the criteria for selecting gene modification therapy applications
- Review of patents for gene editing, gene therapy, RNA therapy and gene modification therapies
- Profiles of the key companies in the market, including 4d Molecular Therapeutics LLC, Abeona Therapeutics LLC, Acer Therapeutics Inc., Allergan Plc and American Gene Technologies International Inc."

COPD Therapeutics in Asia-Pacific Market Size, Growth Opportunities, Trends by Manufacturers | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis

Researchmoz added Most up-to-date research on "COPD Therapeutics in Asia-Pacific Market Size, Growth Opportunities, Trends by Manufacturers | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis" to its huge collection of research reports.

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. It occurs most often in older people, but can also affect the middle aged population. COPD is a major cause of chronic morbidity and mortality globally. Many people suffer from the disease for years and eventually die from it or its complications, meaning it constitutes a substantial economic and social burden. 

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to disease risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke. The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and inhaled corticosteroid (ICS) combinations, bronchodilator monotherapies and PDE-4 inhibitors. 

However, the market is undergoing a gradual transition, moving away from bronchodilator and ICS therapies and towards targeted and triple-combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer broader therapeutic options.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1434918

Scope

• The COPD Asia-Pacific market will be valued at $6.7 billion in 2023, growing from $3.8 billion in 2016 at a CAGR of 8.7%.
• Bronchodilators and ICS therapies dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
• Do branded therapies show continuous growth, and are they facing competition from generics?
• How will branded therapies be affected by upcoming pipeline therapies?
• The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
• Which molecular targets appear most frequently in the pipeline?
• Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
• What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
• Various drivers and barriers will influence the market over the forecast period.
• What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
• What factors are most likely to drive the market in these countries?

Browse TOC @ https://www.researchmoz.us/copd-therapeutics-in-asiapacific-markets-to-2023-growth-driven-by-rising-prevalence-growing-awareness-and-expected-launch-of-novel-therapies-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.

Asia-Pacific Breast Cancer Therapeutics Market to 2024 - Key Players involved in the research Such As Novartis, Pfizer, R-Pharm, Johnson & Johnson, Eli Lily and AstraZeneca

Researchmoz added Most up-to-date research on "Asia-Pacific Breast Cancer Therapeutics Market to 2024 - Key Players involved in the research Such As Novartis, Pfizer, R-Pharm, Johnson & Johnson, Eli Lily and AstraZeneca" to its huge collection of research reports.

Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages of the disease, the survival rate rapidly decreases. HER2-positive breast cancer is an aggressive disease, and historically has had a worse overall survival (OS) than HER2-negative disease, which is considered less aggressive.

The current marketed drug landscape in breast cancer includes a mix of targeted therapies, chemotherapies, and hormonal agents. Metastatic breast cancer is not considered a curable disease, and in the course of therapy patients can receive up to three lines of endocrine agents and four or more lines of chemotherapy, as well as targeted therapies for earlier lines of therapy - often in no particular sequence.

Hormone therapy is the mainstay of treatment for patients with HR-positive disease, but triple-negative breast cancer (TNBC) patients who lack HR expression are normally treated with generic chemotherapies. This is because there are no approved targeted therapies currently available in the TNBC setting. The HER2-positive breast cancer market is dominated by the HER2-targeting mAb Herceptin, the most established drug in this disease area.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1811473

Herceptin is used in nearly all settings of HER2-positive breast cancer and in all markets accessed in this report, as it was demonstrated to significantly improve the OS of women with this disease type. The current breast cancer pipeline is demonstrative of strong innovation in cancer overall, and a significant number of new drug launches are expected during the forecast period.

This is likely to have a significant impact on the competitive landscape, particularly in the early lines of metastatic disease. The emergence of novel biomarkers will also impact treatment decisions for TNBC patients, and will provide new options for targeted therapy in this patient population, fulfilling a long-standing unmet need. One of the key drivers of the breast cancer therapeutics market in the APAC region is the increase in patient volume.

It is also expected to be driven by the anticipated approval of promising therapies within several distinct patient segments, as well as the growing market uptake of already approved therapies in the APAC markets.

Although several branded drugs are expected to go off patent during the forecast period, the impact of this on the market will be offset by the launch of upcoming therapies such as Verzenio, Lynparza, Nerlynx, talazoparib, alpelisib, taselisib, Keytruda, Tecentriq, margetuximab and ipatasertib, and the increasing uptake of already approved therapy such as Ibrance, Kadcyla, Perjeta and Kisqali.

Browse TOC @ https://www.researchmoz.us/breast-cancer-therapeutics-in-asiapacific-markets-to-2024-growth-driven-by-increasing-uptake-of-targeted-therapies-and-rising-prevalence-report.html/toc

Scope

• The breast cancer Asia-Pacific market will be valued at $4.75 billion in 2024, growing from $2.16 billion in 2017 at a compound annual growth rate (CAGR) of 11.9%.
• How will immune checkpoint inhibitors such as Keytruda and Tecentriq, PARP inhibitors such as Lynparza and talazoparib, and PI3K inhibitors such as taselisib and alpelisib contribute to growth?
• What effect will the patent expirations of branded therapies have on market value?
• The breast cancer pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as the lack of targeted therapies available for TNBC patients?
• What implications will the increased focus on targeted therapies have on the future of breast cancer treatment?
• Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• How would the approval of Keytruda, Tecentriq, Lynparza, talazoparib and ipatasertib to treat TNBC patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
• The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
•  How could changes in risk factors such as population age, early menstruation, late menopause, obesity, smoking, lack of breast-feeding and alcohol consumption influence the market?
• Licensing deals are the most common form of strategic alliance in breast cancer, with total deal values ranging from under $10m to over $1 billion.
• How do deal frequency and value compare between target families and molecule types?
• What were the terms and conditions of key licensing deals?

Reasons to buy

This report will enable you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the breast cancer market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict breast cancer market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Asia-Pacific Colorectal Cancer Therapeutics Market Booming with the Major Players Like Taiho Pharma, Merck KGaA, Eli Lilly, Roche, Sanofi and Bayer

Researchmoz added Most up-to-date research on "Asia-Pacific Colorectal Cancer Therapeutics Market Booming with the Major Players Like Taiho Pharma, Merck KGaA, Eli Lilly, Roche, Sanofi and Bayer" to its huge collection of research reports.

Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients.

A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1880947

Scope

• The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
• How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
• What effect will patent expirations of currently branded therapies have on market value?
• The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
• What implications will the increased focus on targeted therapies have on the future of CRC treatment?
• Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
• The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
• How could changes in risk factors such as population age, obesity and lifestyle influence the market?
• Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
• How do deal frequency and value compare between target families and
• molecule types?
• What were the terms and conditions of key licensing deals?

Browse TOC @ https://www.researchmoz.us/colorectal-cancer-therapeutics-in-asiapacific-markets-to-2024-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

Asia-Pacific Colorectal Cancer Therapeutics Market Along With Leading Key Players - Taiho Pharma, Merck KGaA, Hutchison MediPharma, Sanofi, Eli Lilly and Bayer

Researchmoz added Most up-to-date research on "Asia-Pacific Colorectal Cancer Therapeutics Market Along With Leading Key Players - Taiho Pharma, Merck KGaA, Hutchison MediPharma, Sanofi, Eli Lilly and Bayer" to its huge collection of research reports.

Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1880947

In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients.

A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Scope

• The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
• How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
• What effect will patent expirations of currently branded therapies have on market value?
• The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
• What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Browse TOC @ https://www.researchmoz.us/colorectal-cancer-therapeutics-in-asiapacific-markets-to-2024-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html/toc

• Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
• The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
• How could changes in risk factors such as population age, obesity and lifestyle influence the market?
• Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
• How do deal frequency and value compare between target families and
• molecule types?
• What were the terms and conditions of key licensing deals?

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Market to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market

Researchmoz added Most up-to-date research on "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Market to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" to its huge collection of research reports.

Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant proportion of these people are progressing to NASH.

The disease is more frequently progressive and may lead to cirrhosis with complications of hepatocellular carcinoma, liver failure and liver-related death or the requirement of liver transplantation, which is not always feasible. NASH is a major global healthcare problem as the number of NASH patients is increasing.

NASH has been gradually rising in the Asia-Pacific region, owing to the growing prevalence of diabetes, obesity and metabolic syndromes, an aging population and increasingly Westernized lifestyles. Increasing risk factors will result in more people living with the condition and drive revenue growth. Patients with NAFLD and NASH are at increased risk of mortality as well as liver, cardiovascular and malignancy-related death.

The poor long-term prognosis associated with NASH in particular has created a pressing need for improved therapeutic options. At present, there is no approved drug to treat NASH. Lifestyle modification is the initial approach to managing patients with NASH, and then pharmacological treatments such as vitamin E and pioglitazone are recommended as first-line drugs for biopsy-proven NASH.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978076

Significant unmet need exists for NASH-specific products that can treat patients with the condition. NASH-specific therapies, namely selonsertib, elafibranor, Ocaliva and saroglitazar, are in the pipeline for NASH.

Scope

• The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.
• How will the approval of NASH-specific therapies affect the market?
• The NASH market has cheap, generic, off-label drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the NASH market?
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
• How will changes in risk factors such as population age, obesity, type 2 diabetes, NAFLD, metabolic syndrome and lifestyle influence the market?
• The pipeline for NASH therapies is quite diverse with a range of molecule types and molecular targets.
• Which molecular targets appear most frequently in the pipeline?
• How have the late-stage therapies performed in clinical trials?
• The level of unmet need in the NASH market is significantly high. Will the pipeline drugs fulfill these unmet needs?
• Various drivers and barriers will influence the market over the forecast period.
• Licensing deals are the most common form of strategic alliance in NASH, with total deal values ranging from under $10m to over $300m.
• How do deal frequency and value compare between target families and molecule types?
• What were the terms and conditions of key licensing deals?

Browse TOC @ https://www.researchmoz.us/nonalcoholic-steatohepatitis-therapeutics-in-asiapacific-markets-to-2024-launch-of-nashspecific-premium-products-and-rising-prevalence-to-drive-the-market-report.html/toc

Reasons to buy

This report will enable you to:

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the NASH market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the NASH pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict NASH market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the NASH deals landscape by analyzing trends in licensing and co-development deals.

Atopic Dermatitis Therapeutics in Southeast Asia Market Along With Leading Key Players - LEO Pharma, Kang Stem Biotech, Eli Lilly & Incyte Corporation, Amorepacific and Pfizer

Researchmoz added Most up-to-date research on "Atopic Dermatitis Therapeutics in Southeast Asia Market Along With Leading Key Players - LEO Pharma, Kang Stem Biotech, Eli Lilly & Incyte Corporation, Amorepacific and Pfizer" to its huge collection of research reports.

Atopic dermatitis (AD), also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with a characteristic phenotype and typically distributed skin lesions.

It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults globally. AD is a genetically complex, familial transmitted disease with a strong maternal influence; a child possesses a two-fold risk of developing the disease if one of the parents is affected and a three-fold risk if both are affected. Many studies reported that increasing urbanization, westernization of lifestyle, obesity, lack of physical exercise, stress, food allergies, and pollution increase the risk of AD.

The current marketed drug landscape in AD includes topical agents (corticosteroids and calcineurin inhibitors), systemic therapies (such as corticosteroids, cyclosporine, azathioprine, methotrexate and mycophenolatemofetil) and a biologic therapy (Dupixent). Topical steroids have been the mainstay of treatment for AD in both children and adults for the past half century.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978075

The evolution in the understanding of the pathogenesis of AD has led to the discovery and development of several promising treatment options for AD. Recently, two new therapies have been approved for AD, Eucrisa (crisaborole) and Dupixent (dupilumab). However, currently Sanofi/Regeneron’sDupixent is the only targeted therapy that is available in Southeast Asia AD market.

The late-stage AD pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period. These include LEO Pharma’stralokinumab, Eli Lilly’s baricitinib, Kangstem Biotech’s furestem-AD, Pfizer’s PF-04965842 and Amorepacific’s PAC-14028. These new drugs will expand the options available to treat AD patients and contribute to overall market growth by offering novel treatment mechanisms.

Browse TOC @ https://www.researchmoz.us/atopic-dermatitis-therapeutics-in-southeast-asia-markets-to-2024-growth-driven-by-rising-awareness-and-expected-launch-of-novel-therapies-report.html/toc

Scope

• The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%.
• What are the key factors driving the Southeast Asia AD treatment market?
• What classes of drugs dominate the market?
• How will the market respond to recent approval?
• How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?
• The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
• Which classes of novel drugs are most prominent in the pipeline?
• What are the common targets and mechanisms of action of pipeline therapies?
• Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• What are the commercial prospects for the most promising late-stage products?
• How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?
• Various drivers and barriers will influence the market over the forecast period.
• Which factors are most likely to drive the market in these countries?
• What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy

This report will enable you to:

• Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
• Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
• Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising late-stage molecules to market growth.
• Discover trends in licensing and co-development deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.